Dr Fendrick opened the conversation with the commonly prescribed DMARDs (disease-modifying antirheumatic drugs). But the group focused particularly on methotrexate, one of the most commonly prescribed ...

Using a combination of three traditional disease-modifying antirheumatic drugs for treating recent-onset rheumatoid arthritis is more efficient than a monotherapy approach using methotrexate, ...

The chronic nature of rheumatoid arthritis (RA) means that patients require drug therapy for many years. Many RA patients, however, have to discontinue treatment because of drug-related toxic effects, ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

Please provide your email address to receive an email when new articles are posted on . The American College of Rheumatology has released its updated treatment guidelines for rheumatoid arthritis, ...

Using a combination of three traditional disease-modifying antirheumatic drugs for treating recent-onset rheumatoid arthritis is not only more cost-effective, but results in better long-term worker ...

Disease-modifying antirheumatic drugs (DMARDs) are one of the most common therapeutic agent types used in the treatment of rheumatoid arthritis (RA). Despite the fact that DMARDs can retard disease ...

Methotrexate is a first-line rheumatoid arthritis drug that reduces pain and swelling. It may also slow disease progression and help prevent joint damage. Many people notice less pain, swelling, and ...

Methotrexate significantly lowers systolic blood pressure in newly diagnosed RA patients compared to sulfasalazine, potentially reducing cardiovascular risk. The study provides prospective comparative ...

Resistance to DMARDs can be acquired by upregulation of drug-efflux proteins belonging to the family of multidrug-resistance transporters Multidrug-resistance proteins exert primary physiologic ...

Given the long duration of drug treatment that most RA patients face, maintaining the efficacy of DMARDs and biological agents for as long as possible is a challenge. [3,57] When efficacy is ...